Editas Medicine (EDIT -0.98%) and CRISPR Therapeutics (CRSP 1.66%) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets. But as you may have heard, with the recent launch of its first gene therapy, called Casgevy, CRISPR Therapeutics is now a revenue-stage biot ...